Abstract
To the Editor: Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia.1 Frontal fibrosing alopecia (FFA) is considered a clinical variant of LPP.2 Limited evidence supports the therapeutic potential of tofacitinib, a Janus kinase (JAK)-1/3 inhibitor, for the treatment of recalcitrant LPP.3 The aim of our study was to evaluate the efficacy of baricitinib, a JAK-1/2 inhibitor, for the treatment of LPP.4
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
